The headline: 12.4% average body weight reduction at the highest dose over 72 weeks in ATTAIN-1
Tirzepatide, a dual GIP and GLP-1 receptor agonist administered via subcutaneous injection, can cause localized injection site reactions in approximately 3-4% of patients
Clinical Question Is systemic glutathione, as compared to placebo, effective as a skin-whitening agent
Cutting or crushing the tablet would: Disrupt the specialized coating and formulation designed for gastric absorption Potentially alter the pharmacokinetic profile, leading to unpredictable drug levels Reduce bioavailability, as oral semaglutide already has low absorption (approximately 1% bioavailability per FDA labeling) Create inconsistent dosing between the two halves Expose the patient to medication that may not be absorbed effectively The American Diabetes Association guidelines emphasize that medications should be taken as prescribed and formulated unless specifically indicated otherwise by the manufacturer
SURMOUNT-1 Trial Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022) 7
Epigenetic alterations involved in cancer stem cell reprogramming
